m+Medelevator.RU
← Поиск публикаций
Biotechnology and bioengineering · 2026

Next-Generation Glutamine Synthetase Expression Vector for Therapeutic Protein Manufacturing Using CHO Cells.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Johari Yusuf B, Wensley Sophie J, Ammar Malak A, Srivastava Avinash, Ragurajan Changhavi, Patel Jenish, Elliott Natalie C, Hodgson-Casson Alice C, Fedi Mariano Olivera, Anbar Michael, O'Callaghan Peter M, Sweeney Bernie

Аннотация

The glutamine synthetase expression system is widely used for therapeutic protein biomanufacturing in Chinese hamster ovary (CHO) cells. Here, we present the design of an enhanced glutamine synthetase vector for generating CHOK1SV GS-KO stable pools that produce recombinant proteins at multigram-per-liter levels. We first developed a synthetic promoter, LHP-1, for high-level constitutive recombinant gene transcription, achieving up to 123% increase in titer across monoclonal and bispecific antibody formats compared to the viral CMV promoter. We then demonstrate, for the first time, that the bacterial origin of replication (Ori) can function as a core promoter to drive glutamine synthetase selection in CHO cells. In this novel glutamine synthetase vector, Ori and LHP-1 each play dual roles: Ori acts as both the plasmid replication origin and a minimal glutamine synthetase promoter, while LHP-1 drives product expression and optimal enhancement of glutamine synthetase activity without the use of methionine sulfoximine (MSX) supplementation. Together, these two elements further increased product titers by up to 73% compared to the vector harboring the SV40 promoter to drive glutamine synthetase gene expression with 50 µM MSX. Notably, the LHP-1 Ori-GS system effectively maintained high bulk pool titers of up to 5.7 g/L with no decline after 30 days-supporting consistent product yield and quality during culture scale-up for toxicology material supply. Further cell line development showed that clones derived from the LHP-1 Ori-GS pool achieved a 23% higher median titer while maintaining long-term expression stability compared to those generated with the SV40-GS vector, with the top-performing Ori-GS clone reaching 8.3 g/L. Overall, the MSX-free LHP-1 Ori-GS system offers a robust platform for both rapid, high-yield material generation from bulk pools and efficient progression to high-producing clonal cell lines.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты